Kirsten Grunnet

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

Hans Skovgaard Poulsen, Kirsten Grunnet, Morten Mau‐Sørensen et al. · Acta Oncologica · 2008 · 101 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution

Signe Regner Michaelsen, Ib Jarle Christensen, Kirsten Grunnet et al. · BMC Cancer · 2013 · 86 citations · Full text

Medicine, Oncology, Surgery +17

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma

Sidsel Højklint Poulsen, Thomas Urup, Kirsten Grunnet et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2016 · 76 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

Aida Muhic, Hans Skovgaard Poulsen, Morten Mau‐Sørensen et al. · Journal of Neuro-Oncology · 2012 · 71 citations

Medicine, Neurosurgery, Oncology +11

Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET)

Asma Bashir, Sofie Mathilde Jacobsen, Otto Mølby Henriksen et al. · Neuro-Oncology · 2019 · 68 citations · Full text

Medicine, Nuclear Medicine, Oncology +17